209 related articles for article (PubMed ID: 29338092)
1. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer.
Li H; Zhang YQ; Wang C; Zhang X; Li X; Lin YS
Clin Endocrinol (Oxf); 2018 Apr; 88(4):601-606. PubMed ID: 29338092
[TBL] [Abstract][Full Text] [Related]
2. Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer.
Yu F; Li X; Ji Y; Tan J; Zhang G; Wang P; He Y; Wang R
Front Endocrinol (Lausanne); 2021; 12():743310. PubMed ID: 34858329
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
4. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
5. In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.
Zhao T; Liang J; Guo Z; Li T; Lin Y
Clin Nucl Med; 2016 Jun; 41(6):454-8. PubMed ID: 26914559
[TBL] [Abstract][Full Text] [Related]
6. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
7. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
Zhao T; Liang J; Guo Z; Li J; Lin Y
Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
[TBL] [Abstract][Full Text] [Related]
8. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
9. [Significance of Dynamic Risk Assessment in the Follow-up of Non-distant Metastatic Differentiated Thyroid Cancer Patients with Intermediate and High Risk].
Liu JR; Liu YQ; Li H; Liang J; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Apr; 42(2):222-227. PubMed ID: 32385029
[No Abstract] [Full Text] [Related]
10. Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta-analysis.
Cheng F; Xiao J; Huang F; Shao C; Ding S; Yun C; Jia H
Cancer Med; 2022 Jun; 11(12):2386-2396. PubMed ID: 35179295
[TBL] [Abstract][Full Text] [Related]
11. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
12. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
13. Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension.
Wang C; Zhao T; Li H; Gao W; Lin Y
Nucl Med Commun; 2017 May; 38(5):366-371. PubMed ID: 28362717
[TBL] [Abstract][Full Text] [Related]
14. Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis.
Satapathy S; Tupalli A; Chandekar KR; Ballal S; Bal C
Clin Endocrinol (Oxf); 2023 Nov; 99(5):483-491. PubMed ID: 37491776
[TBL] [Abstract][Full Text] [Related]
15. Impact factors of benefiting from initial 131 I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic response.
Ren L; Hu Y; Hu Y; Xiao D; Sun J; Zhu B; Zhang C
Nucl Med Commun; 2024 Mar; 45(3):188-195. PubMed ID: 38165164
[TBL] [Abstract][Full Text] [Related]
16. Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome.
Ciappuccini R; Heutte N; Lasne-Cardon A; Saguet-Rysanek V; Leroy C; Le Hénaff V; Vaur D; Babin E; Bardet S
BMC Cancer; 2020 Aug; 20(1):765. PubMed ID: 32799836
[TBL] [Abstract][Full Text] [Related]
17. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine.
Momesso DP; Vaisman F; Yang SP; Bulzico DA; Corbo R; Vaisman M; Tuttle RM
J Clin Endocrinol Metab; 2016 Jul; 101(7):2692-700. PubMed ID: 27023446
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study.
Kwon SY; Lee SW; Kong EJ; Kim K; Kim BI; Kim J; Kim H; Park SH; Park J; Park HL; Oh SW; Won KS; Ryu YH; Yoon JK; Lee SJ; Lee JJ; Chong A; Jeong YJ; Jeong JH; Cho YS; Cho A; Cheon GJ; Choi EK; Hwang JP; Bae SK;
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):561-571. PubMed ID: 31820047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
